Grant: Catalyst Grant: Environments, Genes and Chronic Disease
University of Guelph
$99,668.00
Investigating the use of biclustering to identify blood mRNA biomarkers to monitor the efficacy and safety of pharmacological and nutritional compounds targeting MetS.
EF 2013-14
Résumé
Metabolic syndrome (MetS) is a common condition characterized by insulin resistance, dyslipidemia, hypertension, and abdominal obesity. Individuals with MetS have an increased risk of cardiovascular disease (CVD) and diabetes. Recent reports estimate that one in five Canadian adults have MetS, highlighting its prevalence in the general population. It is widely accepted that lifestyle modifications such as changing one's diet and exercise habits can be used to prevent MetS. The problem is that most people adopt these new lifestyle habits initially, but quickly revert back to their old "bad" habits. Thus, many people turn to pharmacological and nutritional compounds to help prevent and/or treat MetS. While traditional blood markers (e.g., glucose, free fatty acids) are used in clinical practice to monitor the effects of these compounds, these markers often miss important side effects that can have serious implications on a person's health. This is not surprising given that many pharmacological and nutritional compounds will affect tissues throughout the body. Because people are understandably reluctant to provide tissue samples, alternate screening methods are required. This research proposal will develop a new statistical approach to identify tissue-specific markers that can be measured in blood. This work will use tissue samples from a previous study using obese rats. This proposed work is important for a number of reasons. First, we will obtain a better understanding of how pharmacological and nutritional compounds influence the body. Second, we will develop a powerful new method that identifies blood markers that can reflect tissue function. Finding these new markers will help to better understand how compounds used to prevent and/or treat MetS affect the various tissues in our body, as well as lead to the possible development of new clinical tools that can be used to better monitor the development of side effects.
Programme
Catalyst Grant: Environments, Genes and Chronic Disease
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
285272
Name
Mutch David M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Catalyst Grant: Environments, Genes and Chronic Disease
Projecttitle
Investigating the use of biclustering to identify blood mRNA biomarkers to monitor the efficacy and safety of pharmacological and nutritional compounds targeting MetS.
Programtype2
Operating Grants
Orgnameinp2
University of Guelph
Cihramount2
$99,668
Cihrequipment2
$0
Programname2
Catalyst Grant: Environments, Genes and Chronic Disease
Keyworddelim
Biclustering; Biomarker Discovery; Computational Statistics; Gene Expression; Metabolic Syndrome; Microarray; Nutrigenomics; Peripheral Blood Mononuclear Cells; Resveratrol; Rosiglitazone
Abstract
Metabolic syndrome (MetS) is a common condition characterized by insulin resistance, dyslipidemia, hypertension, and abdominal obesity. Individuals with MetS have an increased risk of cardiovascular disease (CVD) and diabetes. Recent reports estimate that one in five Canadian adults have MetS, highlighting its prevalence in the general population. It is widely accepted that lifestyle modifications such as changing one's diet and exercise habits can be used to prevent MetS. The problem is that most people adopt these new lifestyle habits initially, but quickly revert back to their old "bad" habits. Thus, many people turn to pharmacological and nutritional compounds to help prevent and/or treat MetS. While traditional blood markers (e.g., glucose, free fatty acids) are used in clinical practice to monitor the effects of these compounds, these markers often miss important side effects that can have serious implications on a person's health. This is not surprising given that many pharmacological and nutritional compounds will affect tissues throughout the body. Because people are understandably reluctant to provide tissue samples, alternate screening methods are required. This research proposal will develop a new statistical approach to identify tissue-specific markers that can be measured in blood. This work will use tissue samples from a previous study using obese rats. This proposed work is important for a number of reasons. First, we will obtain a better understanding of how pharmacological and nutritional compounds influence the body. Second, we will develop a powerful new method that identifies blood markers that can reflect tissue function. Finding these new markers will help to better understand how compounds used to prevent and/or treat MetS affect the various tissues in our body, as well as lead to the possible development of new clinical tools that can be used to better monitor the development of side effects.
Competitiondate
201304
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mutch, David M; McNicholas, Paul D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $99,668~ $0~